Go to content

Publications

484 publications

Enter search criteria
Fill in keyword(s) to narrow your search.
Period
You can select a specific type of a publication you are looking for, such as press releases or speeches
Sort by:

  1. Advice - reimburse keto- and hydroxyanalogues (Ketosteril®) for the treatment of severe kidney disease

    The National Health Care Institute has advised the Minister for Medical Care to reimburse keto- and hydroxyanalogues ...

    Report | 25-03-2024

  2. Advice - Reimburse bulevirtide (Hepcludex®) for the treatment of chronic hepatitis delta virus (HDV) infection in certain patients

    The National Health Care Institute has advised the Minister of Health, Welfare and Sport (VWS) to reimburse bulevirtide ...

    Report | 13-03-2024

  3. Advice - reimburse upadacitinib (Rinvoq®) for the treatment of Crohn's disease

    The National Health Care Institute has advised the Minister of Health, Welfare and Sport (VWS) to reimburse upadacitinib ...

    Report | 01-03-2024

  4. International agenda

    The international agenda describes the work of the National Health Care Institute in the international field. We collaborate with ...

    Report | 01-03-2024

  5. Advice - Early discontinuation of conditional inclusion of medicinal products rhPTH 1-84 (Natpar®) and ataluren (Translarna®)

    The National Health Care Institute advises the Minister for Medical Care to discontinue the conditional inclusion of the ...

    Report | 21-02-2024

  6. Advice - Extension of reimbursement conditions for solriamfetol (Sunosi®)

    The National Health Care Institute has advised the Minister of Health, Welfare and Sport (VWS) to extend the List 2 conditions ...

    Report | 16-02-2024

  7. Package advice on the lock procedure medicinal product olaparib (Lynparza®) for the treatment of hereditary breast cancer

    The National Health Care Institute has assessed whether the medicinal product olaparib (Lynparza®) can be reimbursed from the ...

    Report | 13-02-2024

  8. Guideline for economic evaluations in healthcare (2024 version)

    More often considerations are being made about the cost-effectiveness of healthcare intervention what should be reimbursed from ...

    Report | 16-01-2024

  9. Advice - Reimburse voclosporin (Lupkynis®) for the treatment of rare kidney inflammation (lupus nephritis)

    The National Health Care Institute has advised the Minister of Health, Welfare and Sport (VWS) to reimburse voclosporin ...

    Report | 21-12-2023

  10. Advice - Adjustment of reimbursement conditions for lenacapavir (Sunlenca®)

    The National Health Care Institute has advised the Minister of Health, Welfare and Sport (VWS) to adjust the conditions of ...

    Report | 20-12-2023

Go to